Nick Opich News Today

First-ever set of professional guidelines informed by clinical research and expert consensus will set benchmarks for practitioners in an emerging field...

Mydecine Innovations Group, Inc., is pleased to announce that its subsidiary Mindleap Health a digital health platform and the world’s-first telemedicine application purpose-built for the psychedelic medicine industry, has filed a provisional patent for its technology platform in both The United States Patent and Trademark Office and the Canadian Intellectual Property Office. “As our company continues to innovate … Mydecine Innovations Group, Inc., ( CSE:MYCO ) ( OTC:MYCOF ) ( FSE:0NFA ) ...

What: Om of Medicine, one of the leading cannabis provisioning centers serving the Ann Arbor community, is hosting a Meet & Greet with Viola Brands CEO and NBA legend, Al Harrington. Where: 111 S. Main Street, 1st Floor Ann Arbor, MI 48104 When: February 16, 2021 at 4:00-6:00 PM ET Who: Viola Brands CEO and NBA legend, Al Harrington will be onsite along with Om of Medicine Founder and EVP of Operations at Mission Dispensaries Mark Passerini. Both Mark & Al will be available to meet with atten...

Mydecine Innovations Group Appoints Josephine Wu to Board of Directors Mydecine Innovations Group an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for mainstream use, announced the appointment of Josephine Wu, Founder and CIO at Aionious Management, Ltd., to the Company’s Board of Directors. Josh Bartch, Chairman and CEO of Mydecine, stated, “The Board of Directors welcomes Ms. Josephine Wu … Myde...

Mydecine Innovations Group Receives Conditional Approval to List on NEO Exchange Mydecine Innovations Group an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for mainstream use, announced today that it has received Conditional Approval to migrate and uplist its common shares with the NEO Exchange . Final approval is subject to the Company fulfilling all of NEO’s listing requirements. With the impending...

Mydecine Innovations Group Sponsors Study on Neuron Level Response to Psilocybin at University of Maryland Mydecine Innovations Group an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced therapeutic medicine for mainstream use, announced that it is sponsoring a study titled: “Facilitating extinction of fear with psilocybin: Model development of biomarkers and mechanisms,” at the University of Maryland School of ...

Mydecine Innovations Group Files Application to list to the NASDAQ Mydecine Innovations Group an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for mainstream use, announced that it has submitted a formal application to list its common shares on the NASDAQ Stock Exchange . NASDAQ is the second largest exchange by market capitalization worldwide and is home to many of the world’s best … Mydecine Innov...

Mydecine Innovations Group Included in First-Ever Psychedelics ETF Mydecine Innovations Group an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for mainstream use, has been included in the first-ever Psychedelics Exchanged Traded Fund . The Horizons Psychedelic Stock Index ETF index, which was announced in December 2020 and includes 17 companies in the U.S. and Canada, is expected to start … Mydecine I...

Mydecine Innovations Group Appoints Gordon Neal to Board of Directors and Dean Ditto as Chief Financial Officer Mydecine Innovations Group an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for mainstream use, announced that it has appointed veteran corporate finance and capital markets professional, Gordon Neal to the Board of Directors. Additionally, Dean Ditto has joined the Company as Chief Financial ...

Mydecine Innovations Group Engages the ProPharma Group to Proceed with FDA Filings and Approval for Novel Research and Multiple Phase Clinical Trials Mydecine Innovations Group an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced therapeutic medicine for mainstream use, announced that it has partnered with ProPharma Group, the leading provider of regulatory and compliance services to the pharmaceutical, biotech, and...